vs
ANI PHARMACEUTICALS INC（ANIP）とTOMPKINS FINANCIAL CORP（TMP）の財務データ比較。上の社名をクリックして会社を切り替えられます
ANI PHARMACEUTICALS INCの直近四半期売上が大きい（$247.1M vs $194.8M、TOMPKINS FINANCIAL CORPの約1.3倍）。TOMPKINS FINANCIAL CORPの純利益率が高く（49.4% vs 11.1%、差は38.3%）。TOMPKINS FINANCIAL CORPの前年同期比売上増加率が高い（152.7% vs 29.6%）。TOMPKINS FINANCIAL CORPの直近四半期フリーキャッシュフローが多い（$31.9M vs $29.1M）。過去8四半期でTOMPKINS FINANCIAL CORPの売上複合成長率が高い（63.6% vs 34.1%）
ANIファーマシューティカルズは米国に本社を置く特殊製薬会社で、後発医薬品とブランド処方薬の研究開発・製造・販売を行っています。主力製品分野は皮膚科、腫瘍、中枢神経系治療、感染症対策で、主に米国内の医療機関、調剤薬局、患者を対象としています。
トンプキンズ・フィナンシャルはニューヨーク州イサカを本拠とする小規模な多角金融サービス企業です。トンプキンズ信託銀行をはじめ、複数の銀行、保険代理店、ウェルスマネジメント部門の親会社として事業を展開しています。
ANIP vs TMP — 直接比較
損益計算書 — Q4 FY2025 vs Q4 FY2025
| 指標 | | |
|---|---|---|
| 売上 | $247.1M | $194.8M |
| 純利益 | $27.5M | $96.2M |
| 粗利率 | — | — |
| 営業利益率 | 14.1% | 71.7% |
| 純利益率 | 11.1% | 49.4% |
| 売上前年比 | 29.6% | 152.7% |
| 純利益前年比 | 367.5% | 388.9% |
| EPS（希薄化後） | $1.14 | $6.72 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q4 25 | $247.1M | $194.8M | ||
| Q3 25 | $227.8M | $87.4M | ||
| Q2 25 | $211.4M | $82.6M | ||
| Q1 25 | $197.1M | $81.7M | ||
| Q4 24 | $190.6M | $77.1M | ||
| Q3 24 | $148.3M | $76.6M | ||
| Q2 24 | $138.0M | $72.7M | ||
| Q1 24 | $137.4M | $72.8M |
| Q4 25 | $27.5M | $96.2M | ||
| Q3 25 | $26.6M | $23.7M | ||
| Q2 25 | $8.5M | $21.5M | ||
| Q1 25 | $15.7M | $19.7M | ||
| Q4 24 | $-10.3M | $19.7M | ||
| Q3 24 | $-24.2M | $18.6M | ||
| Q2 24 | $-2.3M | $15.7M | ||
| Q1 24 | $18.2M | $16.9M |
| Q4 25 | 14.1% | 71.7% | ||
| Q3 25 | 15.9% | 35.6% | ||
| Q2 25 | 6.6% | 34.2% | ||
| Q1 25 | 13.3% | 31.6% | ||
| Q4 24 | -2.3% | 33.4% | ||
| Q3 24 | -13.8% | 32.0% | ||
| Q2 24 | 3.7% | 28.3% | ||
| Q1 24 | 14.8% | 30.4% |
| Q4 25 | 11.1% | 49.4% | ||
| Q3 25 | 11.7% | 27.1% | ||
| Q2 25 | 4.0% | 26.0% | ||
| Q1 25 | 8.0% | 24.1% | ||
| Q4 24 | -5.4% | 25.5% | ||
| Q3 24 | -16.3% | 24.3% | ||
| Q2 24 | -1.7% | 21.6% | ||
| Q1 24 | 13.2% | 23.2% |
| Q4 25 | $1.14 | $6.72 | ||
| Q3 25 | $1.13 | $1.65 | ||
| Q2 25 | $0.36 | $1.50 | ||
| Q1 25 | $0.69 | $1.37 | ||
| Q4 24 | $-0.45 | $1.39 | ||
| Q3 24 | $-1.27 | $1.30 | ||
| Q2 24 | $-0.14 | $1.10 | ||
| Q1 24 | $0.82 | $1.18 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $285.6M | $132.8M |
| 総負債低いほど良い | — | — |
| 株主資本純資産 | $540.7M | $938.4M |
| 総資産 | $1.4B | $8.7B |
| 負債/資本比率低いほどレバレッジが低い | — | — |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $285.6M | $132.8M | ||
| Q3 25 | $262.6M | $193.5M | ||
| Q2 25 | $217.8M | $212.6M | ||
| Q1 25 | $149.8M | $193.1M | ||
| Q4 24 | $144.9M | $134.4M | ||
| Q3 24 | $145.0M | $132.3M | ||
| Q2 24 | $240.1M | $70.9M | ||
| Q1 24 | $228.6M | $57.1M |
| Q4 25 | $540.7M | $938.4M | ||
| Q3 25 | $505.8M | $788.8M | ||
| Q2 25 | $436.8M | $761.8M | ||
| Q1 25 | $418.6M | $741.4M | ||
| Q4 24 | $403.7M | $713.4M | ||
| Q3 24 | $405.9M | $719.9M | ||
| Q2 24 | $455.8M | $674.6M | ||
| Q1 24 | $452.0M | $667.9M |
| Q4 25 | $1.4B | $8.7B | ||
| Q3 25 | $1.4B | $8.5B | ||
| Q2 25 | $1.3B | $8.4B | ||
| Q1 25 | $1.3B | $8.2B | ||
| Q4 24 | $1.3B | $8.1B | ||
| Q3 24 | $1.3B | $8.0B | ||
| Q2 24 | $920.8M | $7.9B | ||
| Q1 24 | $914.5M | $7.8B |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $30.4M | $38.9M |
| フリーキャッシュフロー営業CF - 設備投資 | $29.1M | $31.9M |
| FCFマージンFCF / 売上 | 11.8% | 16.4% |
| 設備投資強度設備投資 / 売上 | 0.5% | 3.6% |
| キャッシュ転換率営業CF / 純利益 | 1.10× | 0.40× |
| 直近12ヶ月FCF直近4四半期 | $171.4M | $105.0M |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $30.4M | $38.9M | ||
| Q3 25 | $44.1M | $34.9M | ||
| Q2 25 | $75.8M | $18.9M | ||
| Q1 25 | $35.0M | $22.2M | ||
| Q4 24 | $15.9M | $95.0M | ||
| Q3 24 | $12.5M | $21.2M | ||
| Q2 24 | $17.4M | $27.3M | ||
| Q1 24 | $18.3M | $23.2M |
| Q4 25 | $29.1M | $31.9M | ||
| Q3 25 | $38.0M | $33.9M | ||
| Q2 25 | $71.8M | $18.3M | ||
| Q1 25 | $32.5M | $20.9M | ||
| Q4 24 | $13.5M | $88.8M | ||
| Q3 24 | $7.7M | $18.9M | ||
| Q2 24 | $13.0M | $26.3M | ||
| Q1 24 | $13.7M | $21.9M |
| Q4 25 | 11.8% | 16.4% | ||
| Q3 25 | 16.7% | 38.8% | ||
| Q2 25 | 34.0% | 22.1% | ||
| Q1 25 | 16.5% | 25.5% | ||
| Q4 24 | 7.1% | 115.1% | ||
| Q3 24 | 5.2% | 24.7% | ||
| Q2 24 | 9.4% | 36.2% | ||
| Q1 24 | 10.0% | 30.0% |
| Q4 25 | 0.5% | 3.6% | ||
| Q3 25 | 2.7% | 1.1% | ||
| Q2 25 | 1.9% | 0.8% | ||
| Q1 25 | 1.3% | 1.7% | ||
| Q4 24 | 1.3% | 8.1% | ||
| Q3 24 | 3.2% | 2.9% | ||
| Q2 24 | 3.2% | 1.3% | ||
| Q1 24 | 3.3% | 1.9% |
| Q4 25 | 1.10× | 0.40× | ||
| Q3 25 | 1.66× | 1.47× | ||
| Q2 25 | 8.87× | 0.88× | ||
| Q1 25 | 2.23× | 1.13× | ||
| Q4 24 | — | 4.82× | ||
| Q3 24 | — | 1.14× | ||
| Q2 24 | — | 1.74× | ||
| Q1 24 | 1.00× | 1.38× |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
ANIP
| Sales Of Cortrophin Gel | $111.4M | 45% |
| Sales Of Generic Pharmaceutical Products | $100.8M | 41% |
| Sales Of ILUVIEN And YUTIQ | $19.8M | 8% |
| Sales Of Established Brands | $12.3M | 5% |
| Unapproved Products | $6.5M | 3% |
| Sales Of Royalties And Other Pharmaceutical Services | $2.7M | 1% |
TMP
セグメントデータなし
